TY - JOUR
T1 - Anticancer drugs acting against signaling pathways
AU - Powis, G.
PY - 1995
Y1 - 1995
N2 - This review deals with anticancer drugs with activity against signaling targets that have been studied in cancer patients. The major categories of drugs studied so far are modulators of the activity of protein kinase C, inhibitors of protein kinase A, protein tyrosine kinase, and receptor- operated Ca2+ channels. Drugs that may modulate ras function have also been studied. None of the agents have yet received extensive clinical trials. Toxicities and anecdotal cases of antitumor activity have been reported. There are a number of other anticancer drugs with activity against signaling targets awaiting clinical trial.
AB - This review deals with anticancer drugs with activity against signaling targets that have been studied in cancer patients. The major categories of drugs studied so far are modulators of the activity of protein kinase C, inhibitors of protein kinase A, protein tyrosine kinase, and receptor- operated Ca2+ channels. Drugs that may modulate ras function have also been studied. None of the agents have yet received extensive clinical trials. Toxicities and anecdotal cases of antitumor activity have been reported. There are a number of other anticancer drugs with activity against signaling targets awaiting clinical trial.
UR - http://www.scopus.com/inward/record.url?scp=0028793659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028793659&partnerID=8YFLogxK
U2 - 10.1097/00001622-199511000-00014
DO - 10.1097/00001622-199511000-00014
M3 - Review article
C2 - 8547405
AN - SCOPUS:0028793659
SN - 1040-8746
VL - 7
SP - 554
EP - 559
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 6
ER -